A Novel β-lactam/β-lactamase Inhibitor: Ceftolozane/tazobactam

A Novel β-lactam/β-lactamase Inhibitor: Ceftolozane/tazobactam

Ceftolozane/tazobactam is a novel generation cephalosporin and β-lactamase inhibitor combination antibiotic. It was approved for the treatment of adults (18 years and older) with complicated intraabdominal infections used in combination with metronidazole and complicated urinary tract infections by...

Full description

Bibliographic Details
Main Author:	Kıvanç ŞEREFHANOĞLU
Format:	Article
Language:	Turkish
Published:	Galenos Yayinevi 2019-12-01
Series:	Mediterranean Journal of Infection, Microbes and Antimicrobials
Subjects:	cre esbl hemodialysis chronic kidney disease complicated intra-abdominal infections
Online Access:	http://mjima.org/text.php?&id=165

Similar Items

Ceftolozane/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy
by: Escolà-Vergé L, et al.
Published: (2019-07-01)

Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam
by: Myra W. Popejoy, et al.
Published: (2017-05-01)

Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres
by: Elizabeth B. Hirsch, et al.
Published: (2020-09-01)

Ceftolozane/tazobactam – the "new player" in a battle against multiresistant pathogens
by: Golub A.V., et al.
Published: (2018-11-01)

Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections
by: Hidalgo JA, et al.
Published: (2016-07-01)

Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
by: Marco Fiore, et al.
Published: (2021-01-01)

Multimodal Interventions to Prevent and Control Carbapenem-Resistant Enterobacteriaceae and Extended-Spectrum β-Lactamase Producer-Associated Infections at a Tertiary Care Hospital in Egypt
by: Noha A. Kamel, et al.
Published: (2021-04-01)

Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)
by: Thitima Kongnakorn, et al.
Published: (2019-12-01)

Detection of Extended Spectrum β-lactamase Production Among Uropathogens
by: Ritu Aggarwal, et al.
Published: (2009-01-01)

Vacuum-Assisted Abdominal Closure in Surgical Emergency: A Single Institution Experience Treating a Cohort with a Prevalence of Faecal Peritonitis
by: Skicko Dmitrijs, et al.
Published: (2021-04-01)

Bacterial profile and patterns of antimicrobial drug resistance in intra-abdominal infections: Current experience in a teaching hospital
by: Neetu Shree, et al.
Published: (2013-01-01)

Comparison of therapy with β-lactam/β-lactamase inhibitor combinations or carbapenems for bacteraemia of nonurinary source caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae
by: Hong Luo, et al.
Published: (2021-09-01)

Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination
by: Hong MC, et al.
Published: (2013-11-01)

Ceftolozane/Tazobactam and Ceftazidime/Avibactam for Multidrug-Resistant Gram-Negative Infections in Immunocompetent Patients: A Single-Center Retrospective Study
by: Rosario Cultrera, et al.
Published: (2020-09-01)

Efficacy and safety of eravacycline: A meta-analysis
by: Khalid Eljaaly, et al.
Published: (2021-03-01)

Antimicrobial resistance comparison of Klebsiella pneumoniae pathogens isolated from intra-abdominal and urinary tract infections in different organs, hospital departments and regions of China between 2014 and 2017
by: Hui Zhang, et al.
Published: (2021-08-01)

Frequency, associated factors and outcome of multi-drug-resistant intensive care unit-acquired pneumonia among patients colonized with extended-spectrum β-lactamase-producing Enterobacteriaceae
by: Keyvan Razazi, et al.
Published: (2017-06-01)

Colonization with selected antibiotic resistant bacteria among a cohort of Sri Lankan university students
by: Thilini Munasinghe, et al.
Published: (2021-06-01)

Sulfamoyl Heteroarylcarboxylic Acids as Promising Metallo-β-Lactamase Inhibitors for Controlling Bacterial Carbapenem Resistance
by: Jun-ichi Wachino, et al.
Published: (2020-03-01)

Frequency of extended spectrum β-Lactamase producing Enterobacteriaceae in intensive care units
by: Mirsalehian.A, et al.
Published: (2007-06-01)

Comparison of antimicrobial activity between ceftolozane–tazobactam and ceftazidime–avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa
by: Adnan Alatoom, et al.
Published: (2017-09-01)

Persistent Extended-Spectrum β-Lactamase Urinary Tract Infection
by: Joan DeBusscher, et al.
Published: (2009-11-01)

Extended-spectrum β-lactamase bla CTX-M-1 group in gram-negative bacteria colonizing patients admitted at Mazimbu hospital and Morogoro Regional hospital in Morogoro, Tanzania
by: Nyambura Moremi, et al.
Published: (2021-02-01)

Factor influencing outcome of source control in the management of complicated intra-abdominal infection in Cipto Mangunkusumo University Hospital
by: Toar Jean Maurice Lalisang, et al.
Published: (2019-01-01)

Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors
by: Giacomo Luci, et al.
Published: (2021-06-01)

Effect of Mealtime During Hemodialysis on Patients’ Complications
by: Seyed Reza Borzou, et al.
Published: (2016-12-01)

Extended-spectrum β-lactamase-producing enterobacteriaceae in community-acquired urinary tract infections in São Luís, Brazil
by: Afonso Gomes Abreu, et al.
Published: (2013-01-01)

Trends in antimicrobial resistance in Israel, 2014–2017
by: Yaakov Dickstein, et al.
Published: (2019-06-01)

Multi-drug resistant Gram negative bacilli in cockroaches collected from hospital and community environments in Lebanon
by: Ahmad Sleiman, et al.
Published: (2020-12-01)

An overview of the antimicrobial resistance mechanisms of bacteria
by: Wanda C Reygaert
Published: (2018-06-01)

Phylogenetic and Transmission Patterns of Extended-Spectrum β- Lactamase –Producing Escherichia Coli among Neonatal’s Gut Flora in Indonesia
by: Rakhmatul Binti Sulistya, et al.
Published: (2021-09-01)

Induction of plasmid-mediated AmpC β-lactamase DHA-1 by piperacillin/tazobactam and other β-lactams in Enterobacteriaceae.
by: Kentaro Akata, et al.
Published: (2019-01-01)

Antimicrobial susceptibility and distribution of extended-spectrum β-lactamases, AmpC β-lactamases and carbapenemases among Proteus, Providencia and Morganella isolated from global hospitalised patients with intra-abdominal and urinary tract infections: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2008–2011
by: Jui-Hsuan Yang, et al.
Published: (2020-09-01)

In Silico Analysis of Extended-Spectrum β-Lactamases in Bacteria
by: Patrik Mlynarcik, et al.
Published: (2021-07-01)

Distribution of extended-spectrum β-lactamase types in a Brazilian tertiary hospital
by: Keite da Silva Nogueira, et al.
Published: (2015-04-01)

PROBLEMS OF COMPLICATED INTRA-ABDOMINAL INFECTION’S ANTIBACTERIAL TREATMENT IN MULTIDISCIPLINARY HOSPITALS
by: Yu. M. Gomon, et al.
Published: (2017-12-01)

The Efficacy and Safety of Eravacycline in the Treatment of Complicated Intra-Abdominal Infections: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
by: Shao-Huan Lan, et al.
Published: (2019-06-01)

Delayed Initiation of Hemodialysis in Pregnant Women with Chronic Kidney Disease: Logistical Problems Impact Clinical Outcomes. An Experience from an Emerging Country
by: Juan Carlos H Hernández Rivera, et al.
Published: (2019-04-01)

Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial
by: Jean-François Timsit, et al.
Published: (2021-08-01)

Cost-effectiveness of ceftolozane/tazobactam for the treatment of complicated intraabdominal and urinary tract infections in Colombia
by: Fabián Hernández
Published: (2020-02-01)